Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Spain.
Clin Liver Dis. 2010 May;14(2):297-305. doi: 10.1016/j.cld.2010.03.012.
Current recommendations for the treatment of acute variceal bleeding (AVB) are to combine hemodynamic stabilization, antibiotic prophylaxis, pharmacologic agents, and endoscopic treatment. However, despite the application of the current gold-standard pharmacologic and endoscopic treatment, failure to control bleeding or early rebleed within 5 days still occurs in 15% to 20% of patients with AVB. In case of treatment failure of the acute bleeding episode, if bleeding is mild and the patient is hemodynamically stable, a second endoscopic therapy may be attempted. If this fails, or if bleeding is severe, it is usually controlled temporarily with balloon tamponade until a definitive derivative treatment is applied. Transjugular intrahepatic portosystemic shunt is highly effective in this situation; however, despite the control of bleeding, a high proportion of these patients die of liver and multiorgan failure. Strategies intended to improve the prognosis of these patients should focus on identifying those high-risk patients in whom standard therapy is likely to fail, and who are therefore candidates for more aggressive therapies early after the development of AVB.
目前,急性静脉曲张出血(AVB)的治疗建议是将血流动力学稳定、抗生素预防、药物治疗和内镜治疗结合起来。然而,尽管应用了目前的金标准药物和内镜治疗,仍有 15%至 20%的 AVB 患者在 5 天内无法控制出血或早期再出血。如果急性出血发作的治疗失败,如果出血较轻且患者血流动力学稳定,可以尝试再次进行内镜治疗。如果治疗失败,或者出血严重,通常可以通过球囊填塞暂时控制出血,直到进行确定性的衍生治疗。经颈静脉肝内门体分流术(TIPS)在这种情况下非常有效;然而,尽管出血得到了控制,但这些患者中有很大一部分死于肝和多器官衰竭。旨在改善这些患者预后的策略应侧重于识别那些标准治疗可能失败的高危患者,这些患者是在发生 AVB 后早期接受更积极治疗的候选者。